计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| A127274-5mg |
5mg |
现货 ![]() |
| |
| A127274-25mg |
25mg |
现货 ![]() |
| |
| A127274-100mg |
100mg |
现货 ![]() |
|
| 别名 | 4-(4-氟-3-((4-甲氧基哌啶-1-基)羰基)苄基)酞嗪-1(2H)-酮 |
|---|---|
| 英文别名 | NCGC00381558-06 | 4-{[4-Fluoro-3-(4-methoxypiperidine-1-carbonyl)phenyl]methyl}phthalazin-1(2H)-one | BDBM50288530 | s7029 | 1174043-16-3 | HYNBNUYQTQIHJK-UHFFFAOYSA-N | 3K288XF5XJ | AC-36007 | 4-(4-fluoro-3-(4-methoxypiperidine-1-carbonyl)benzyl)phthalaz |
| 规格或纯度 | Moligand™, ≥98% |
| 英文名称 | AZD2461 |
| 生化机理 | 强大的PARP抑制剂(PARP2,PARP1和PARP3的IC50值分别为2、5和200 nM)。在BRCA1突变体中具有抗癌作用,但在野生型乳腺癌细胞系中则无。在小鼠模型中抑制抗奥拉帕尼的乳腺肿瘤的生长,并且是P-gp转运蛋白的不良底物。口服具有生物活性。 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 产品介绍 |
AZD2461是新型PARP抑制剂,能够避免由Pgp介导的olaparib抗性。 AZD2461 is a novel PARP inhibitor, which has the potential to avoid the olaparib resistence mediated by Pgp. |
| 纯度 | ≥98% |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| 分子类型 | 小分子 |
|---|---|
| IIUPAC Name | 4-[[4-fluoro-3-(4-methoxypiperidine-1-carbonyl)phenyl]methyl]-2H-phthalazin-1-one |
| INCHI | 1S/C22H22FN3O3/c1-29-15-8-10-26(11-9-15)22(28)18-12-14(6-7-19(18)23)13-20-16-4-2-3-5-17(16)21(27)25-24-20/h2-7,12,15H,8-11,13H2,1H3,(H,25,27) |
| InChi Key | HYNBNUYQTQIHJK-UHFFFAOYSA-N |
| Smiles | COC1CCN(CC1)C(=O)C2=C(C=CC(=C2)CC3=NNC(=O)C4=CC=CC=C43)F |
| Isomeric SMILES | COC1CCN(CC1)C(=O)C2=C(C=CC(=C2)CC3=NNC(=O)C4=CC=CC=C43)F |
| 分子量 | 395.43 |
| Reaxy-Rn | 19333597 |
| Reaxys-RN link address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=19333597&ln= |
| 溶解性 | 溶于DMSO, 最高浓度 (mg/mL): 39.54, 最高浓度(mM): 100;溶于ethanol, 最高浓度 (mg/mL): 39.54, 最高浓度(mM): 100 |
|---|---|
| 分子量 | 395.400 g/mol |
| XLogP3 | 2.600 |
| 氢键供体数Hydrogen Bond Donor Count | 1 |
| 氢键受体数Hydrogen Bond Acceptor Count | 5 |
| 可旋转键计数Rotatable Bond Count | 4 |
| 精确质量Exact Mass | 395.165 Da |
| 单同位素质量Monoisotopic Mass | 395.165 Da |
| 拓扑极表面积Topological Polar Surface Area | 71.000 Ų |
| 重原子数Heavy Atom Count | 29 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 647.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| 1. Graziani G, Szabó C. (2005) Clinical perspectives of PARP inhibitors.. Pharmacol Res, 52 (1): (109-18). [PMID:15911339] |
| 2. Jaspers JE, Kersbergen A, Boon U, Sol W, van Deemter L, Zander SA, Drost R, Wientjens E, Ji J, Aly A et al.. (2013) Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.. Cancer Discov, 3 (1): (68-81). [PMID:23103855] |